Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $160,226.00 in Stock

Posted by Brenda Bartman on Jun 28th, 2026

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) EVP Michael David Garrison sold 1,100 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael David Garrison also recently made the following trade(s):

On Wednesday, June 10th, Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $151.48, for a total value of $166,628.00.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $156.06 on Friday. The company has a 50 day moving average price of $148.17 and a 200 day moving average price of $170.75. The firm has a market capitalization of $43.00 billion, a P/E ratio of 39.51, a PEG ratio of 11.04 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the prior year, the business posted $3.35 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BDX shares. Argus decreased their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Bank of America reduced their price target on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Stifel Nicolaus cut their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $181.00.

Check Out Our Latest Analysis on Becton, Dickinson and Company

Institutional Trading of Becton, Dickinson and Company

Several institutional investors have recently bought and sold shares of the business. Ravenstone Capital Management Inc. purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at approximately $7,465,000. Defilade Capital Management L.P. increased its holdings in Becton, Dickinson and Company by 243.8% in the 1st quarter. Defilade Capital Management L.P. now owns 279,210 shares of the medical instruments supplier’s stock worth $43,900,000 after acquiring an additional 198,003 shares in the last quarter. DV Trading LLC acquired a new position in Becton, Dickinson and Company during the first quarter worth $236,000. Parallel Advisors LLC lifted its holdings in Becton, Dickinson and Company by 16.7% during the first quarter. Parallel Advisors LLC now owns 4,071 shares of the medical instruments supplier’s stock valued at $640,000 after purchasing an additional 582 shares in the last quarter. Finally, NewEdge Advisors LLC grew its position in shares of Becton, Dickinson and Company by 35.0% in the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after purchasing an additional 11,414 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.